<!DOCTYPE html>
<html>

  <head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width initial-scale=1" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge">

  <title>Adam A. Saleh | publications</title>
  <meta name="description" content="Adam A. Saleh publications">

  

  <link rel="shortcut icon" href="/assets/img/favicon.ico">

  <link rel="stylesheet" href="/assets/css/main.css">
  <link rel="canonical" href="/publications/">
</head>


  <body>

    <header class="site-header">

  <div class="wrapper">

    
    <span class="site-title">
        
        <strong>Adam</strong> A. Saleh
    </span>
    

    <nav class="site-nav">
      <input type="checkbox" id="nav-trigger" class="nav-trigger" />
        <label for="nav-trigger">
          <span class="menu-icon">
            <svg viewBox="0 0 18 15" width="18px" height="15px">
              <path fill="#424242" d="M18,1.484c0,0.82-0.665,1.484-1.484,1.484H1.484C0.665,2.969,0,2.304,0,1.484l0,0C0,0.665,0.665,0,1.484,0 h15.031C17.335,0,18,0.665,18,1.484L18,1.484z"/>
              <path fill="#424242" d="M18,7.516C18,8.335,17.335,9,16.516,9H1.484C0.665,9,0,8.335,0,7.516l0,0c0-0.82,0.665-1.484,1.484-1.484 h15.031C17.335,6.031,18,6.696,18,7.516L18,7.516z"/>
              <path fill="#424242" d="M18,13.516C18,14.335,17.335,15,16.516,15H1.484C0.665,15,0,14.335,0,13.516l0,0 c0-0.82,0.665-1.484,1.484-1.484h15.031C17.335,12.031,18,12.696,18,13.516L18,13.516z"/>
            </svg>
          </span>
        </label>

      <div class="trigger">
        <!-- About -->
        <a class="page-link" href="/">about</a>

        <!-- Blog -->
        <a class="page-link" href="/blog/">blog</a>

        <!-- Pages -->
        
        
          
            <a class="page-link" href="/projects/">projects</a>
          
            <a class="page-link" href="/abstracts/">abstracts</a>
          
            <a class="page-link" href="/publications/">publications</a>
          
        
          
            <!--<a class="page-link" href="/teaching/">teaching</a> -->


        <!-- CV link -->
        <!-- <a class="page-link" href="/assets/pdf/CV.pdf">vitae</a> -->

      </div>
    </nav>

  </div>

</header>



    <div class="page-content">
      <div class="wrapper">
        <div class="post">

  <header class="post-header">
    <h1 class="post-title">publications</h1>
    <h5 class="post-description">Publications by categories in reversed chronological order. </h5>
  </header>

  <article class="post-content publications clearfix">
 
<h3 class="year">2022</h3>
<ol class="bibliography"><li>
<div id="einstein1956investigations">
  
    <span class="title">Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician</span>
    <span class="author">
          
            <em><b>Saleh, Adam</b></em>,
            <em>Ansari, U.</em>,
            <em>Abughazaleh, S.</em>,
            <em>Glassner, K.</em>,
            <a href="https://www.houstonmethodist.org/doctor/bincy-abraham/">Abraham, B.</a> 
          
    </span>

    <span class="periodical">
    
      Biologics: Targets and Therapy, June 2022
    
    </span>
  

  <span class="links">
  
      [<a class="abstract">Abs</a>]
      [<a href="https://doi.org/10.2147/BTT.S335697" target="_blank">DOI</a>]

  
  </span>

  <!-- Hidden abstract block -->
    <span class="abstract hidden">
    <p>Several biologic therapies have been approved for enteric diseases. We evaluate each biologic’s role based on their mechanism of action in treating these conditions. This review examines data on efficacy and safety, as well as considerations for using these therapies in clinical practice in inflammatory bowel diseases, enteric infections—specifically Clostridioides difficile colitis—and potentially in the increasingly prevalent disorder of eosinophilic esophagitis. When choosing an appropriate therapy, it is important to assess patient severity, as most biologics are approved for those with moderate to severe disease activity. With many years of data from clinical trials and real-world experience, these therapies have been shown to improve outcomes overall in enteric diseases, contributing to more options for our patients.

</p>
  </span>
</li></ol>

<h3 class="year">2023</h3>
<ol class="bibliography"><li>
<div id="einstein1956investigations">
  
    <span class="title">The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis</span>
    <span class="author">
          
            <em><b>Saleh, Adam</b></em>,
            <em>Parsa, S.</em>,
            <em>Garza, M.</em>,
            <em>Quigley, E.M.M.</em>,
            <a href="https://www.houstonmethodist.org/doctor/bincy-abraham/">Abraham, B.</a> 
          
    </span>

    <span class="periodical">
    
      Digestive Diseases, March 2023
    
    </span>
  

  <span class="links">
  
      [<a class="abstract">Abs</a>]
      [<a href="https://doi.org/10.1159/000529591" target="_blank">DOI</a>]

  
  </span>

  <!-- Hidden abstract block -->
    <span class="abstract hidden">
    <p>Background: Considerable research supports an important role for the microbiome and/or microbiome–host immune system interactions in the pathogenesis of inflammatory bowel disease (IBD). Consequently, microbiota-modulating interventions, such as fecal microbiota transplantation (FMT), have attracted interest in the management of IBD, including ulcerative colitis (UC). Summary: While the clinical response to FMT in UC has varied between different studies, results to date may offer guidance towards optimal use of FMT. Thus, increased microbiome biodiversity, the presence of short-chain fatty acid producing bacteria, Clostridium Cluster IV and XIVa, Odoribacter splanchnicus and reduced levels of Caudovirales bacteriophages have been identified as characteristics of the donor microbiome that predict a positive response. However, inconsistency in FMT protocol between studies confounds their interpretation, so it is currently difficult to predict response and premature to recommend FMT, in general, as a treatment for UC. Additional randomized controlled trials designed based on previous findings and employing a standardized protocol are needed to define the role of FMT in the management of UC. Key Messages: There is a well-developed rationale for the use of microbiome-modulating interventions in UC. Despite variations in study protocol and limitations in study design that confound their interpretation, FMT seems to benefit patients with UC, overall. Available data identify factors predicting FMT response and should lead to the development of optimal FMT study protocols.

</p>
  </span>
</li></ol>


</div>

      </div>
    </div>

    <footer>

  <div class="wrapper">
    &copy; Copyright 2020 Adam Saleh.
    Powered by <a href="http://jekyllrb.com/" target="_blank">Jekyll</a> with <a href="https://github.com/alshedivat/al-folio">al-folio</a> theme. Hosted by <a href="https://pages.github.com/" target="_blank">GitHub Pages</a>.

    
  </div>

</footer>


    <!-- Load jQuery -->
<script src="//code.jquery.com/jquery-1.12.4.min.js"></script>

<!-- Load Common JS -->
<script src="/assets/js/common.js"></script>


<!-- Load KaTeX -->
<link rel="stylesheet" href="//cdnjs.cloudflare.com/ajax/libs/KaTeX/0.9.0/katex.min.css">
<script src="//cdnjs.cloudflare.com/ajax/libs/KaTeX/0.9.0/katex.min.js"></script>
<script src="/assets/js/katex.js"></script>




<!-- Include custom icon fonts -->
<link rel="stylesheet" href="/assets/css/fontawesome-all.min.css">
<link rel="stylesheet" href="/assets/css/academicons.min.css">


<!-- Google Analytics -->
<script>
(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,'script','//www.google-analytics.com/analytics.js','ga');

ga('create', 'UA-XXXXXXXXX', 'auto');
ga('send', 'pageview');
</script>



  </body>

</html>
